Viking’s new dual GLP-1R/GIPR agonist expected to start Phase III trials soon
American biopharmaceutical company Viking Therapeutics is actively developing several candidates aimed at treating metabolic disorders. Among these is VK2735, a…
American biopharmaceutical company Viking Therapeutics is actively developing several candidates aimed at treating metabolic disorders. Among these is VK2735, a…